1. Home
  2. CTSO vs EEA Comparison

CTSO vs EEA Comparison

Compare CTSO & EEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTSO
  • EEA
  • Stock Information
  • Founded
  • CTSO 1997
  • EEA 1986
  • Country
  • CTSO United States
  • EEA Germany
  • Employees
  • CTSO N/A
  • EEA N/A
  • Industry
  • CTSO Medical/Dental Instruments
  • EEA Trusts Except Educational Religious and Charitable
  • Sector
  • CTSO Health Care
  • EEA Finance
  • Exchange
  • CTSO Nasdaq
  • EEA Nasdaq
  • Market Cap
  • CTSO 51.6M
  • EEA 57.7M
  • IPO Year
  • CTSO N/A
  • EEA N/A
  • Fundamental
  • Price
  • CTSO $1.08
  • EEA $9.04
  • Analyst Decision
  • CTSO Strong Buy
  • EEA
  • Analyst Count
  • CTSO 3
  • EEA 0
  • Target Price
  • CTSO $4.67
  • EEA N/A
  • AVG Volume (30 Days)
  • CTSO 159.7K
  • EEA 9.2K
  • Earning Date
  • CTSO 05-08-2025
  • EEA 01-01-0001
  • Dividend Yield
  • CTSO N/A
  • EEA 1.92%
  • EPS Growth
  • CTSO N/A
  • EEA N/A
  • EPS
  • CTSO N/A
  • EEA N/A
  • Revenue
  • CTSO $37,739,531.00
  • EEA N/A
  • Revenue This Year
  • CTSO $9.20
  • EEA N/A
  • Revenue Next Year
  • CTSO $11.64
  • EEA N/A
  • P/E Ratio
  • CTSO N/A
  • EEA N/A
  • Revenue Growth
  • CTSO 1.80
  • EEA N/A
  • 52 Week Low
  • CTSO $0.70
  • EEA $7.45
  • 52 Week High
  • CTSO $1.61
  • EEA $9.26
  • Technical
  • Relative Strength Index (RSI)
  • CTSO 45.16
  • EEA 55.70
  • Support Level
  • CTSO $0.99
  • EEA $9.08
  • Resistance Level
  • CTSO $1.15
  • EEA $9.48
  • Average True Range (ATR)
  • CTSO 0.08
  • EEA 0.14
  • MACD
  • CTSO -0.02
  • EEA -0.01
  • Stochastic Oscillator
  • CTSO 10.53
  • EEA 33.93

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

About EEA The European Equity Fund Inc.

European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.

Share on Social Networks: